Navigation Links
KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Company's ADHD Prodrug Technology
Date:8/16/2010

e pay particular attention to how we can differentiate our products from potential prior art before we ever synthesize a molecule utilizing LAT.  We are pleased that the USPTO has acknowledged the novel aspects and non-obvious results generated by our ADHD portfolio and granted protection of our discoveries."

About KP106KP106, KemPharm's lead prodrug candidate for the treatment of ADHD, is composed of d-amphetamine and a ligand.  In preclinical studies, KP106 demonstrated unique abuse deterrent properties along with pharmacokinetics indicative of an attenuated amphetamine exposure as compared to Vyvanse®.  These data predict that patients receiving KP106 may experience decreased side effects and decreased risk of abuse typically associated with stimulants.  Importantly, KemPharm is positioning KP106 to be the first ever proprietary thin film dosage form for ADHD to address compliance issues, in particular, for the pediatric patient population.  KemPharm projects the filing of a new drug application (NDA) for KP106 by the end of 2012.

About KemPharm, Inc.KemPharm, Inc. is focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable LAT prodrug approach.  KemPharm utilizes its LAT prodrug technology to generate improved versions of FDA-approved drugs.  Each NCE creates new composition-based intellectual property, may have a shorter development timeline and reduced development costs, and may be eligible for 505(b)(2) regulatory submission.  The Company's business strategy includes seeking strategic development partners following rapid clinical proof of concept demonstration in a Phase 1 trial.  KemPharm also plans to explore discovery stage alliances with industry leaders, leveraging its prodrug know-how and LAT technology platform.  KemPharm is developing candidates for ADHD, pain, other centra
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. PDL BioPharma Receives Letter from Genentech Relating to European Patents
2. Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research
3. PolyGel® Receives SADMERC Approval for L-Code L3670 for ThermoActive™ Cold & Hot Mobile Compression Shoulder Orthosis
4. Accurays CyberKnife® G4 System Receives Shonin Approval
5. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH®
6. Abbotts SIMCOR ® ( niacin extended-release / simvastatin ) Receives FDA Approval for New Dosage Strengths
7. Instrumentation Laboratory Receives FDA Clearance for New Automated Total Bilirubin Assay on GEM Premier 4000 Critical Care Analyzer
8. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
9. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
10. CardioGenics Holdings Inc. Receives New Ticker Symbol
11. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ... SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting and ... will be held at the San Diego ... California , from May 20 - 22.  ... analytical system, incorporating commercial audio-visual technologies into new and ...
(Date:5/17/2013)... 17, 2013  ConvaTec today announced that it will report its 2013 ... , CEO, and Ed Borkowski , CFO, will ... telephone. To participate in the conference call within the ... To participate in the conference call outside the U.S. and ... is 72195398. Participants should dial in 10 minutes prior to ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
Breaking Medicine Technology:Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
... , , NEW YORK, ... of FairChoice Health, its campus health management service, in ... FairChoice Health empowers campus health officers to alert students ... track vaccination compliance. FairChoice Health is the first ...
... , , LONDON, July ... through a cancer treatment that changed her life -- and made history ... world to receive an injection of tumor-activated natural killer (TaNK) cells as ... the Royal Free Hospital in London recommended this experimental therapy after two ...
Cached Medicine Technology:Online H1N1 Management: FairChoice Helps Schools Respond to Infectious Disease on Campus 2British Woman Celebrates a Year of Living Cancer-Free 2British Woman Celebrates a Year of Living Cancer-Free 3British Woman Celebrates a Year of Living Cancer-Free 4
(Date:5/18/2013)... 18, 2013) There are significant cost and ... to diagnose or treat gastrointestinal problems, according to ... , A study by New York Presbyterian Hospital ... testing may substantially reduce the cost and risk ... is believed to affect nearly 25 percent of ...
(Date:5/18/2013)... 18, 2013 Today, Zane Benefits, ... agents’ role in Marketplaces . Zane Benefits, which ... sponsored health benefits, is the leader in health ... health reimbursement arrangements . , According to Zane ... Services (HHS) recently released a much-anticipated statement and ...
(Date:5/18/2013)... York, NY (PRWEB) May 18, 2013 After ... consistent efforts, SizeItUp formally announced the integration of ... redesigned 2012 Hyundai Genesis is set to stun the automobile ... and style. 2012 Hyundai Genesis is marked as the latest ... and heads the vehicles lined up for the year 2013. ...
(Date:5/18/2013)... Although obesity is associated with an increased risk ... esophageal adenocarcinoma, a type of esophageal cancer, is stronger ... on Cancer.gov, last reviewed in January 2012, overweight ... those of normal and healthy weight to develop this ... cancer is not well understood, it is now thought ...
(Date:5/18/2013)... Show And Go Training, the culmination of Eric ... that is all about is getting results in the fastest ... http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting an investigative review. , ... phase system” designed to make you faster, stronger, fitter and ... out in the gym. The training manual and exercise video ...
Breaking Medicine News(10 mins):Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
... Inc. (Nasdaq: VNUS ), a leading provider of ... disease, today,announced that it presented at the William Blair ... on October 3, 2007, at the New York,Palace Hotel ... the VNUS presentation webcast is available on the,corporate website ...
... SAN DIEGO, Oct. 3 Anadys Pharmaceuticals,Inc. (Nasdaq: ... BIO,InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 ... at The Palace Hotel in San,Francisco. Steve Worland, ... will present an overview of Anadys and an update ...
... A new Web site from Northwood,Health Systems has ... a five-year development effort in partnership with the best,Web ... perfect the,application of Web site technology," Northwood President and ... http://www.NorthwoodHealth.com, offers more than 1,000 accredited,continuing education courses ...
... NORCROSS, Ga., Oct. 3 Immucor, Inc. (Nasdaq:,BLUD), ... to,the blood transfusion industry, today reported financial results ... Revenue for the fiscal first quarter was ... in the same period last year. Of the ...
... Oct. 3 The patent lawsuit,by VNUS(R) Medical Technologies, ... Diomed, AngioDynamics and Vascular Solutions,is set to proceed to ... by both sides. In its motions VNUS had asked ... infringed the VNUS patents,while the defendants countered with their ...
... will work, experts say , WEDNESDAY, Oct. 3 (HealthDay ... help doctors determine the best chemotherapy for patients, U.S. ... tumors would be most likely to respond to standard ... has traditionally been a second-line therapy, based on gene ...
Cached Medicine News:Health News:Anadys Pharmaceuticals to Present at BIO InvestorForum 2007 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 3Health News:Immucor Announces Record Fiscal First Quarter Revenues 4Health News:Immucor Announces Record Fiscal First Quarter Revenues 5Health News:Immucor Announces Record Fiscal First Quarter Revenues 6Health News:Immucor Announces Record Fiscal First Quarter Revenues 7Health News:Immucor Announces Record Fiscal First Quarter Revenues 8Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 2Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 3Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
AchilloTrain is a comfortable knitted support with a silicone insert alongside the Achilles tendon and under the heel. An additional heel cushion is provided for the unaffected foot. It is worn to tr...
DarcoGel™ Upper chamber is foam filled, conforms to calf; gel-filled lower chamber molds to the malleoli for a custom fit. Freeze the removable liner for cold therapy. One size. Fits left or ri...
... maintaining the ankle in functional alignment. Entire ... cushioning AliPlast™ foam liner. The cushioning air ... heel in a protective hammock, reducing ulceration ... bed from side-lying to supine. Only the ...
Medicine Products: